ContactIGES Pharma France
Local Insight. Global Impact.
Pierre Moïse, General Manager France
France's Access Landscape: Structured, Demanding – and Evolving
France’s healthcare system is one of the largest and most complex in Europe, providing universal coverage through the Sécurité Sociale. While the French market offers significant opportunities, it also presents distinct challenges for market access. The key stakeholders in the market include the Haute Autorité de Santé (HAS), which is responsible for deciding on reimbursement (SMR) and evaluating the clinical added value (ASMR) of new medicines, and the Comité économique des produits de santé (CEPS), which negotiates prices with pharmaceutical companies.
While the French market offers significant opportunities, it also presents distinct challenges for market access. Key challenges include a high threshold for demonstrating clinical added value for reimbursement, lengthy pricing negotiations which can delay market entry, and exacting methodological standards for clinical evidence. However, opportunities exist through early involvement in the HTA process, as well as early access for innovative medicines (Accès Précoce), a key component for any successful pricing and market access strategy for France. Strategic planning and a deep understanding of the local market are essential to successfully navigate these challenges and capitalize on the opportunities.
IGES Pharma France – Who We are and What We Bring to the Table
Led by a senior team with over 40 years’ experience supporting pharmaceutical companies’ pricing and market access needs in France, IGES Pharma France offers a comprehensive range of pricing and market access capabilities necessary for successful pricing and reimbursement in France.
From in-depth analyses of clinical studies to identify potential evidence gaps, to developing a pricing strategy that considers product characteristics, our solutions are tailored to optimize pricing and reimbursement in France. Below are a few examples that show how our team spans the spectrum of IGES capabilities.
It starts with early access where we can help develop an early access program, Autorisation Accès Précoce.
Following marketing approval, we can submit reimbursement dossiers for submission to the Commission de la Transparence, including accompanying clients to meetings with the Haute Autorité de Santé. Once reimbursement has been secured, we can help clients prepare for price negotiations with the Comité Economique des Produits de Santé.
Prior to marketing authorization, we can leverage our local market access expertise to support the development of your pricing and market access strategy in France. Furthermore, our real strength lies not just in our local market expertise for France but, just as importantly, how we integrate that expertise with that of IGES Pharma as a whole, to develop successful European pricing and market access strategies.
With the advent of EU HTA, IGES Pharma’s contribution to the development of the EU HTA process and experience developing AMNOG dossiers is a real advantage to support PICO scoping and full-service EU HTA dossier submissions, in concert with local market access experts across Europe.
Let’s Make Access Happen
How to Contact Our Team:
pharma@iges.com
Paris Office: 34 Avenue des Champs Elysees, 75008 Paris, France
